Skip to main content
Sister Publication Links
  • ModernHealthcare.com
Subscribe
  • My Account
  • Login
  • Register
  • Consumer Centric
  • Provider/Payer Centric
  • Funding/M&A
  • Policy
  • Data
  • Opinion
  • MORE+
    • Webinars
    • Advertise
MENU
Breadcrumb
  1. Home
  2. Policy
June 15, 2022 10:18 AM

Cerebral reportedly adds FTC investigation to its list of troubles

Gabriel Perna
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    cerebral

    Cerebral, the embattled digital mental health company, is reportedly being investigated by the U.S. Federal Trade Commission for potentially deceptive cancellation practices. 

    A Cerebral spokesperson declined to specifically comment on whether it was being investigated. However, the spokesperson said the company was fully cooperating with the FTC.

    The Wall Street Journal reported on June 14 that the FTC sent a letter to Cerebral requesting information on whether the company has continued to charge patients even after they’ve attempted to cancel their subscription. According to the report, the FTC has asked Cerebral to preserve relevant documents. 

    The FTC not have a comment on the reported investigation. 

    Sign up for Digital Health Business & Technology's newsletters to stay informed on industry trends

    An investigation would represent the second federal agency that has looked into Cerebral in the past two months. The company received a grand jury subpoena from the U.S. Attorney’s Office for the Eastern District of New York on May 4 to investigate “possible violations of the Controlled Substances Act” related to how its prescribed medication for ADHD.

    In mid-May, Cerebral’s previous CEO Kyle Robertson was forced out and replaced by Dr. David Mou, who previously served as the company's president and chief medical officer. Robertson’s departure came after mounting criticism of the startup's prescribing practices, including three lawsuits by former employees and the investigation from the U.S. Attorney’s Office.. 

    CVS Health, Walmart and TruePill have stopped filling prescriptions from the company, while health insurer Aetna has stopped covering its services. In response, the company has announced it will no longer prescribe certain controlled substances to treat ADHD.

    Amid these challenges, Cerebral said it was restructuring its operations and eliminating a number of positions by July 1, although it did not specify how many employees would be laid off. According to an internal memo obtained by Digital Health Business & Technology, the affected areas will include support and operations teams within the company’s San Francisco headquarters. The company has 2,500 employees.

    In December 2021, Cerebral received a $300 million funding round and has a valuation of nearly $5 billion.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it online.

    Recommended for You
    woman_on_phone_getty_edit_i.jpg
    After Roe, Dems seek probe of tech’s use of personal data
    telehealth abortion
    With Roe v. Wade overturned, telehealth providers brace for impact
    Sponsored Content
    Get Newsletters

    Newsletters for providers, payers, investors and innovators across the digital health ecosystem. Sign up to get breaking digital health news including digital health deals, M&A, finance, IPOs. as they happen, right to your inbox.

    Buy Q1 Report Today
    Quarterly Report Cover Image

    The Digital Health Funding and M&A Q1 report delivers the most comprehensive insight and data around the financial health of the sector.

    Purchase Today
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Digital Health Business & Technology delivers news, data, insights and analysis covering the entire digital healthcare ecosystem.

    Logo
    Contact Us

    (877) 812-1581

    Email us

     

    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    Resources
    • About Us
    • Contact Us
    • Staff
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Digital Health Business & Technology
    Copyright © 1996-2022. Crain Communications, Inc. All Rights Reserved.
    • Consumer Centric
    • Provider/Payer Centric
    • Funding/M&A
    • Policy
    • Data
    • Opinion
    • MORE+
      • Webinars
      • Advertise